Previous Close | 51.83 |
1-Year Change | 106.41% |
6-Months Change | 84.51% |
3-Months Change | 50.36% |
Moving Avg (50d) | 46.461 |
Moving Avg (200d) | 32.978 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 5.29B |
Beta (3-Years) | 0.79 |
Revenue Growth (ttm) | 13.18% |
Net Profit Margin (ttm) | 20.31% |
Return On Assets (ttm) | 15.38% |
EPS (ttm) | 0.81 |
PE Ratio (ttm) | 63.99 |
Dividend Yield | % |
Asset Description: | Corcept Therapeutics Incorporated |
Predicted Direction: | Sell |
Signal Strength: | Sell |
Forecast Date: | 2024-11-13 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
57.212 | 58.895 | 60.016 | 61.699 | 64.504 | 67.308 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Biotechnology |
Country: | United States |
Corcept Therapeutics Inc. is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. Corcept has focused on the adverse effects of excess cortisol, studying new compounds that may mitigate those effects. Its executive team is headed by CEO, president and director Joseph K. Belanoff, MD,... Wikipedia